Amgen Inc. convinced a U.S. appeals court on Wednesday to uphold patents that bar generic versions of its blockbuster psoriasis drug Otezla proposed by Zydus Pharmaceuticals and Novartis AG’s Sandoz Inc until 2028.
Posts
A U.S. appeals court ordered Jazz Pharmaceuticals Inc. on Friday to de-list a patent related to its blockbuster narcolepsy drug Xyrem from the U.S. Food and Drug Administration’s register of approved medications, in a win for rival drugmaker Avadel CNS Pharmaceuticals Inc.
A U.S. appeals court on Tuesday ruled against Swiss drugmaker Novartis AG in a patent infringement dispute concerning its blockbuster multiple sclerosis drug Gilenya.
